{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T23:53:11Z","timestamp":1772581991134,"version":"3.50.1"},"reference-count":0,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[1997,7,1]],"date-time":"1997-07-01T00:00:00Z","timestamp":867715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[1997,7]]},"abstract":"<jats:p>SCH 56592 (SCH) is a new triazole antifungal with a broad spectrum of activity. In vitro susceptibility testing against five strains of Coccidioides immitis revealed MICs from 0.39 to 3.13 microg\/ml and minimal fungicidal concentrations from 1.56 to 3.13 microg\/ml. A murine model of systemic coccidioidomycosis was established in female CD-1 mice. Groups received either no treatment or oral therapy with fluconazole at 10 or 100 mg\/kg of body weight; itraconazole at 10 or 100 mg\/kg; SCH at 0.5, 2, 10, or 25 mg\/kg; or its methylcellulose diluent alone. Therapy began 2 days postinfection and continued once daily for 19 days. Surviving mice were euthanized 49 days postinfection, and infectious burdens were determined by culture. All drugs were superior to no-treatment or diluent-treatment controls (P &lt; 0.001) in prolonging survival but were not significantly different from one another. Itraconazole at 100 mg\/kg was superior to fluconazole in reduction of CFU in the spleen, liver, and lung (P &lt; 0.01 to 0.001). SCH at 0.5 mg\/kg was superior to either fluconazole or itraconazole at 10 mg\/kg in reduction of CFU in all three organs (P &lt; 0.05 to 0.001). SCH at 2 mg\/kg was not significantly different from itraconazole at 100 mg\/kg in all three organs. SCH at 10 and 25 mg\/kg was superior to either dose of fluconazole or itraconazole in all three organs (P &lt; 0.05 to 0.001). In terms of reduction of CFU, SCH was &gt; or = 200-fold as potent as fluconazole and &gt; or = 50-fold as potent as itraconazole. There was a clear dose-responsive relationship for SCH in each of the organs. It is noteworthy that SCH effected cures (no detectable C. immitis in any organ) in 1 of 9, 6 of 10, or 9 of 9 surviving mice in animals given 2, 10, or 25 mg\/kg, respectively. Neither fluconazole nor itraconazole cured any survivor. SCH has potent, fungicidal activity in vivo against C. immitis. It should be considered for clinical trials in patients with coccidioidomycosis.<\/jats:p>","DOI":"10.1128\/aac.41.7.1558","type":"journal-article","created":{"date-parts":[[2018,10,9]],"date-time":"2018-10-09T00:28:57Z","timestamp":1539044937000},"page":"1558-1561","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":81,"title":["Activity of the triazole SCH 56592 against disseminated murine coccidioidomycosis"],"prefix":"10.1128","volume":"41","author":[{"given":"J E","family":"Lutz","sequence":"first","affiliation":[{"name":"Department of Medicine, Santa Clara Valley Medical Center, and California Institute for Medical Research, San Jose 95128, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K V","family":"Clemons","sequence":"additional","affiliation":[{"name":"Department of Medicine, Santa Clara Valley Medical Center, and California Institute for Medical Research, San Jose 95128, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B H","family":"Aristizabal","sequence":"additional","affiliation":[{"name":"Department of Medicine, Santa Clara Valley Medical Center, and California Institute for Medical Research, San Jose 95128, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D A","family":"Stevens","sequence":"additional","affiliation":[{"name":"Department of Medicine, Santa Clara Valley Medical Center, and California Institute for Medical Research, San Jose 95128, USA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.41.7.1558","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.41.7.1558","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:11:43Z","timestamp":1645474303000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.41.7.1558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,7]]},"references-count":0,"journal-issue":{"issue":"7","published-print":{"date-parts":[[1997,7]]}},"alternative-id":["10.1128\/AAC.41.7.1558"],"URL":"https:\/\/doi.org\/10.1128\/aac.41.7.1558","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,7]]},"assertion":[{"value":"1997-07-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}